3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
49
Stomach Neoplasms
11
Neoplasms
10
HER2-positive Breast Cancer
8
Colorectal Neoplasms
8
Neoplasm Metastasis
7
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Interventions
sacubitril and valsartan sodium hydrate drug combination
2
dapagliflozin
2
Rituximab
2
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
acalabrutinib
1
Vincristine
1
Valsartan
1
Trastuzumab
1
Standard of Care
1
Specimen Handling
1
Pyruvic Acid
1
Prednisolone
1
Practice Guidelines as Topic
1
Ogivri
1
Mesenchymal Stem Cell Transplantation
1
Lenalidomide
1
Eplerenone
1
Electronic Health Records
1
Echocardiography
1
Doxorubicin
1
Dexrazoxane
1
Cyclophosphamide
1
Cardiac Resynchronization Therapy
1
Angiotensin-Converting Enzyme Inhibitors
1
Adrenergic beta-Antagonists
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Heart Failure
×
Trastuzumab
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled